Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Who can join
28 Days · All sexes
Full eligibility criteria
The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and exclusion criteria that determine eligibility for randomization within the Platform. Another level is that, once eligible for inclusion within the Platform, additional criteria (typically exclusion criteria) are applied that are specific to each domain. Finally, intervention-level eligibility criteria may be applied for interventions within a domain. A patient is eligible for inclusion within a domain when: * All Platform inclusion criteria are met * None of the Platform exclusion criteria are met * Domain-specific eligibility criteria are met * The patient is eligible for at least two interventions within a domain As such, the key "inclusion criteria" for being eligible for a domain are that the patient is eligible for the Platform. \-- PLATFORM INCLUSION CRITERIA: 1. Hospitalised patient 2. Acute respiratory tract infection 3. Aged 28 days or older PLATFORM EXCLUSION CRITERIA: 1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 2. Patient is expected to be discharged from hospital within the next 24 hours 3. Previous participation in this REMAP within the last 90 days DOMAIN-SPECIFIC ELIGIBILITY CRITERIA: Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
About the study
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
What is being tested
- Ceftriaxone + Macrolide (drug)
- Moxifloxacin or Levofloxacin (drug)
- Piperacillin-tazobactam + Macrolide (drug)
- Ceftaroline + Macrolide (drug)
- Amoxicillin-clavulanate + Macrolide (drug)
- Standard course macrolide (drug)
Sponsor: UMC Utrecht · Participants: 20,000 · Started: Apr 11, 2016
Contact the study team
Official record on ClinicalTrials.gov — NCT02735707
Locations in the U.S.
| Florida | University of Florida, Jacksonville |
| Georgia | Augusta University, Augusta (Not yet recruiting) |
| Illinois | University of Illinois Health, Chicago |
| Louisiana | Tulane Medical Center, New Orleans (Not yet recruiting) |
| Michigan | University of Michigan, Ann Arbor |
| New York | Memorial Sloan Kettering Cancer Center, New York |
| North Carolina | Wake Forest Baptist Health, Winston-Salem (Not yet recruiting) |
| Ohio | The Ohio State University Wexner Medical Center, Columbus |
| Oregon | Oregon Health and Science University, Portland |
| Pennsylvania | University of Pittsburgh Medical Centre, Pittsburgh |
| Rhode Island | Brown University - Rhode Island Hospital, Providence (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.